DK2250498T3 - Lægemiddelvalg til brystcancerterapi under anvendelse af antistof-baserede arrays - Google Patents
Lægemiddelvalg til brystcancerterapi under anvendelse af antistof-baserede arraysInfo
- Publication number
- DK2250498T3 DK2250498T3 DK09715619.4T DK09715619T DK2250498T3 DK 2250498 T3 DK2250498 T3 DK 2250498T3 DK 09715619 T DK09715619 T DK 09715619T DK 2250498 T3 DK2250498 T3 DK 2250498T3
- Authority
- DK
- Denmark
- Prior art keywords
- choices
- antibody
- pharmaceutical
- breast cancer
- cancer therapy
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3131908P | 2008-02-25 | 2008-02-25 | |
US10640408P | 2008-10-17 | 2008-10-17 | |
US10838408P | 2008-10-24 | 2008-10-24 | |
US11790808P | 2008-11-25 | 2008-11-25 | |
US14055808P | 2008-12-23 | 2008-12-23 | |
PCT/US2009/035013 WO2009108637A1 (en) | 2008-02-25 | 2009-02-24 | Drug selection for breast cancer therapy using antibody-based arrays |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2250498T3 true DK2250498T3 (da) | 2013-02-04 |
Family
ID=40599946
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK09715619.4T DK2250498T3 (da) | 2008-02-25 | 2009-02-24 | Lægemiddelvalg til brystcancerterapi under anvendelse af antistof-baserede arrays |
DK12183659.7T DK2602623T3 (da) | 2008-02-25 | 2009-02-24 | Fremgangsmåde til detekteringen af intracellulært trunkerede receptorer |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK12183659.7T DK2602623T3 (da) | 2008-02-25 | 2009-02-24 | Fremgangsmåde til detekteringen af intracellulært trunkerede receptorer |
Country Status (13)
Country | Link |
---|---|
US (4) | US8163499B2 (da) |
EP (3) | EP2250498B1 (da) |
JP (2) | JP5414701B2 (da) |
CN (2) | CN102016581B (da) |
AU (1) | AU2009219437B2 (da) |
CA (2) | CA2716826C (da) |
DK (2) | DK2250498T3 (da) |
ES (3) | ES2553390T3 (da) |
HK (2) | HK1182441A1 (da) |
IL (3) | IL207637A (da) |
MX (1) | MX2010009140A (da) |
NZ (3) | NZ587420A (da) |
WO (1) | WO2009108637A1 (da) |
Families Citing this family (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2557286T3 (es) * | 2003-03-03 | 2016-01-25 | Dyax Corp. | Usos de péptidos que se unen específicamente al receptor del HGF (cMet) |
CN102886045A (zh) | 2005-02-03 | 2013-01-23 | 综合医院公司 | 治疗吉非替尼耐药性癌症的方法 |
EP1942937A1 (en) | 2005-11-04 | 2008-07-16 | Wyeth | Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272 |
BRPI0717416A2 (pt) | 2006-09-21 | 2013-11-12 | Prometheus Lab Inc | Método para realizar um imunoensaio complexo de alta produtividade, e, arranjo |
BRPI0813583A2 (pt) | 2007-07-13 | 2014-12-30 | Prometheus Lab Inc | Métodos para selecionar um medicamento anticâncer, para identificar a resposta de um tumor pulmonar, e para prognosticar a resposta de um paciente, e, arranjo |
US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
WO2009108637A1 (en) | 2008-02-25 | 2009-09-03 | Prometheus Laboratories, Inc. | Drug selection for breast cancer therapy using antibody-based arrays |
PL2310011T3 (pl) | 2008-06-17 | 2013-12-31 | Wyeth Llc | Kombinacje przeciwnowotworowe zawierające HKI-272 i vinorelbine |
SG10202102855RA (en) | 2008-08-04 | 2021-05-28 | Wyeth Llc | Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine |
GB2467691A (en) | 2008-09-05 | 2010-08-11 | Aueon Inc | Methods for stratifying and annotating cancer drug treatment options |
WO2010085845A1 (en) * | 2009-01-28 | 2010-08-05 | The University Of Queensland | Cancer therapy and/or diagnosis |
MX356593B (es) | 2009-04-06 | 2018-06-05 | Wyeth Llc | Régimen de tratamiento que utiliza neratinib para cáncer de mama. |
CA2761777A1 (en) | 2009-05-14 | 2010-11-18 | Prometheus Laboratories Inc. | Biomarkers for determining sensitivity of breast cancer cells to her2-targeted therapy |
PT2473854T (pt) * | 2009-06-23 | 2017-10-17 | Fundação D Anna De Sommer Champalimaud E Dr Carlos Montez Champalimaud | Sistemas e métodos para tratar, diagnosticar e prever a resposta à terapia do cancro de mama |
ES2627909T3 (es) * | 2009-07-15 | 2017-08-01 | Diatech Holdings, Inc. | Selección de fármacos para el tratamiento del cáncer gástrico usando matrices basadas en anticuercuerpos |
WO2011015920A2 (en) * | 2009-08-03 | 2011-02-10 | Avesthagen Limited | A highly efficient process of purification and production of recombinant trastuzumab |
WO2011015921A1 (en) * | 2009-08-03 | 2011-02-10 | Avesthagen Limited | A highly efficient process of purification and production of recombinant cetuximab |
WO2011034919A2 (en) * | 2009-09-15 | 2011-03-24 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Sh2 domain profiling to characterize tyrosine phosphorylation signaling in cancer |
JP5819307B2 (ja) * | 2009-10-20 | 2015-11-24 | ネステク ソシエテ アノニム | 発癌性融合タンパク質を検出するための近接媒介性アッセイ |
RU2558931C2 (ru) * | 2010-01-12 | 2015-08-10 | Нестек С.А. | Способы предсказания ответа трижды негативного рака молочной железы на терапию |
US8338456B2 (en) | 2010-01-13 | 2012-12-25 | Wyeth Llc | Cut-point in PTEN protein expression that accurately identifies tumors and is predictive of drug response to a pan-ErbB inhibitor |
WO2012006421A2 (en) | 2010-07-07 | 2012-01-12 | The Regents Of The University Of Michigan | Diagnosis and treatment of breast cancer |
TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
EP2619329B1 (en) | 2010-09-24 | 2019-05-22 | The Board of Trustees of The Leland Stanford Junior University | Direct capture, amplification and sequencing of target dna using immobilized primers |
EP2656077A1 (en) | 2010-12-23 | 2013-10-30 | Nestec S.A. | Drug selection for malignant cancer therapy using antibody-based arrays |
US9962361B2 (en) | 2011-01-03 | 2018-05-08 | The William M. Yarbrough Foundation | Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use |
US20140024539A1 (en) * | 2011-02-02 | 2014-01-23 | Translational Genomics Research Institute | Biomarkers and methods of use thereof |
US9719995B2 (en) | 2011-02-03 | 2017-08-01 | Pierian Holdings, Inc. | Drug selection for colorectal cancer therapy using receptor tyrosine kinase profiling |
US9532969B2 (en) | 2011-02-08 | 2017-01-03 | The William M. Yarbrough Foundation | Method for treating psoriasis |
RU2578848C2 (ru) | 2011-02-17 | 2016-03-27 | Нестек С.А. | Устройство и способ выделения лейкоцитов и раковых клеток путем фильтрования |
WO2012154253A1 (en) | 2011-02-17 | 2012-11-15 | Prometheus Laboratories Inc. | ASSAYS FOR DETECTING AUTOANTIBODIES TO ANTI-TNFα DRUGS |
EP2908132B8 (en) | 2011-03-02 | 2019-06-12 | Nestec S.A. | Prediction of drug sensitivity of lung tumors based on molecular and genetic signatures |
AU2012240242A1 (en) * | 2011-04-04 | 2013-10-10 | Nestec S.A. | Methods for predicting and improving the survival of gastric cancer patients |
BR112013028808A2 (pt) | 2011-05-10 | 2016-09-06 | Nestec Sa | métodos de caracterização de perfil de atividade de doença para a gestão de terapia personalizada |
WO2013026027A1 (en) | 2011-08-18 | 2013-02-21 | Nestec S.A. | Compositions and methods for detecting allelic variants |
KR101851425B1 (ko) | 2011-09-02 | 2018-04-23 | 네스텍 소시에테아노님 | 치료 효능 결정을 위한 신호 경로 단백질의 프로파일링 |
ES2607649T3 (es) * | 2011-11-04 | 2017-04-03 | Invivis Sas | Ensayo para biomarcadores predictivos de la eficacia antiestrogénica |
JP2015505959A (ja) * | 2011-12-05 | 2015-02-26 | ネステク ソシエテ アノニム | 癌を有する患者に治療を選択する方法 |
CN103157109A (zh) * | 2011-12-12 | 2013-06-19 | 中国科学院生物物理研究所 | Cd146及其抗体诊断和治疗三阴性乳腺癌的应用 |
EP2798085B1 (en) * | 2011-12-30 | 2018-01-24 | Quest Diagnostics Investments Incorporated | Aptamers and diagnostic methods for detecting the egf receptor |
US20130330761A1 (en) | 2012-06-12 | 2013-12-12 | Celcuity, LLC | Whole cell assays and methods |
US10335387B2 (en) | 2012-07-26 | 2019-07-02 | The William M. Yarbrough Foundation | Method for treating infectious diseases with isothiocyanate functional compounds |
US10434082B2 (en) | 2012-07-26 | 2019-10-08 | The William M. Yarbrough Foundation | Isothiocyanate functional compounds augmented with secondary antineoplastic medicaments and associated methods for treating neoplasms |
US10434081B2 (en) | 2012-07-26 | 2019-10-08 | The William M. Yarbrough Foundation | Inhibitors of macrophage migration inhibitory factor |
US10441561B2 (en) | 2012-07-26 | 2019-10-15 | The William M. Yanbrough Foundation | Method for treating benign prostatic hyperplasia (BPH), prostatitis, and prostate cancer |
US20150212087A1 (en) * | 2012-07-27 | 2015-07-30 | Centre Leon Berard | Detection of the ERalpha/Src/PI3K Complex as Predictive Marker in Breast Cancer |
AU2013326070A1 (en) | 2012-10-05 | 2015-04-23 | Société des Produits Nestlé S.A. | Methods for predicting and monitoring mucosal healing |
CN113156139A (zh) * | 2013-01-03 | 2021-07-23 | 梅索磅秤技术有限公司 | 测定实验对象组 |
EP2954328A1 (en) | 2013-02-05 | 2015-12-16 | Nestec S.A. | Drug selection for colorectal cancer therapy using receptor tyrosine kinase profiling |
EP2954329A1 (en) | 2013-02-05 | 2015-12-16 | Nestec S.A. | Methods of selecting combination therapy for colorectal cancer patients |
WO2014122582A1 (en) | 2013-02-05 | 2014-08-14 | Nestec S.A. | Drug selection for non-small cell lung cancer therapy |
CA2904181A1 (en) | 2013-03-13 | 2014-10-09 | Anahit Aghvanyan | Sandwich immunoassay comprising anchoring reagent |
US10114015B2 (en) | 2013-03-13 | 2018-10-30 | Meso Scale Technologies, Llc. | Assay methods |
JP6663347B2 (ja) * | 2013-03-15 | 2020-03-11 | ヤンセン ファーマシューティカ エヌ.ベー. | 予測バイオマーカーのためのアッセイ |
EP2984088B1 (en) * | 2013-04-12 | 2019-03-20 | Asana BioSciences, LLC | Quinazolines and azaquinazolines as dual inhibitors of ras/raf/mek/erk and pi3k/akt/pten/mtor pathways |
MX2015016065A (es) | 2013-05-21 | 2016-03-21 | Nestec Sa | Metodos para predecir y mejorar la supervivencia de pacientes de cancer colorrectal. |
EP3019867A1 (en) | 2013-07-09 | 2016-05-18 | Nestec S.A. | Microfluidic collaborative enzyme enhanced reactive ceer immunoassay |
EP3039429B1 (en) | 2013-08-30 | 2018-10-10 | Nestec S.A. | Polyp recurrence |
ES2729638T3 (es) * | 2013-10-11 | 2019-11-05 | Ventana Med Syst Inc | Ensayos múltiplex de tinción conjunta de receptores de HER2 y de estrógenos para detectar heterogeneidad tumoral |
US20160273045A1 (en) * | 2013-10-23 | 2016-09-22 | Oregon Health & Science University | Methods of determining breast cancer prognosis |
WO2015083085A1 (en) | 2013-12-03 | 2015-06-11 | Nestec S.A. | Signaling pathways in tissues from inflammatory bowel disease patients |
WO2015089380A2 (en) | 2013-12-12 | 2015-06-18 | Celcuity Llc | Assays and methods for determining the responsiveness of an individual subject to a therapeutic agent |
US9730935B2 (en) * | 2013-12-13 | 2017-08-15 | The Board Of Trustees Of The Leland Stanford Junior University | Targeting a non-canonical notch signaling pathway for cancer treatment |
CN106574927A (zh) * | 2014-01-14 | 2017-04-19 | 崔元哲 | 使用luterial的形态学特征筛选癌症预防剂或抗癌剂的方法 |
WO2015110989A1 (en) | 2014-01-23 | 2015-07-30 | Nestec S.A. | Biomarker panel for assessment of mucosal healing |
WO2015166461A1 (en) | 2014-05-01 | 2015-11-05 | Nestec S.A. | Methods of selecting treatment regimen using tnf alpha and anti-tnf alpha drug levels |
JP6695280B2 (ja) | 2014-05-15 | 2020-05-20 | メソ スケール テクノロジーズ エルエルシー | 改善されたアッセイ方法 |
CN104083762A (zh) * | 2014-06-27 | 2014-10-08 | 中国科学院生物物理研究所 | 用于阻断Netrin-1与CD146之间的相互作用的试剂及其肿瘤治疗用途 |
EP3210016A1 (en) | 2014-10-20 | 2017-08-30 | Nestec S.A. | Methods for prediction of anti-tnf alpha drug levels and autoantibody formation |
MX2017006959A (es) | 2014-12-02 | 2017-08-10 | Nestec Sa | Metodos para establecer un regimen de dosificacion de vedolizumab para tratar pacientes con enfermedad del intestino irritable. |
AU2015360260B2 (en) * | 2014-12-12 | 2021-10-28 | Celcuity Inc. | Methods of measuring ErbB signaling pathway activity to diagnose and treat cancer patients |
JP6720138B2 (ja) * | 2015-03-13 | 2020-07-08 | シスメックス株式会社 | 被検物質の検出方法およびその方法に用いられる試薬キット |
US10724071B2 (en) | 2015-10-14 | 2020-07-28 | Nitto Boseki Co., Ltd. | Method for determining drug-sensitive human cell lines by analysis method in which measurement of activity of two types of protein kinase is used |
KR20190015360A (ko) * | 2016-05-31 | 2019-02-13 | 네스텍 소시에테아노님 | Her2 및 her3 경로 아형 분류를 기반으로 한, 유방암 환자에 대한 약물 치료법의 선택 방법 |
CN107727752B (zh) * | 2016-08-12 | 2019-11-08 | 北大方正集团有限公司 | 免疫抑制剂依维莫司的分析方法 |
JP6779483B2 (ja) | 2016-09-29 | 2020-11-04 | 住友ゴム工業株式会社 | 医療用検査装置及び細胞検査方法 |
JP6518985B2 (ja) | 2016-09-29 | 2019-05-29 | 住友ゴム工業株式会社 | がん細胞捕捉方法 |
CN106645728A (zh) * | 2016-11-09 | 2017-05-10 | 百奥森(江苏)食品安全科技有限公司 | 一种食品中氟喹诺酮类药物的检测试剂盒 |
WO2018103834A1 (en) * | 2016-12-07 | 2018-06-14 | Fundació Privada Institut D'investigació Oncológica De Vall D'hebron | Her2 as a predictor of response to dual her2 blockade in the absence of cytotoxic therapy |
EP3879269A3 (en) | 2017-03-20 | 2021-11-17 | Celcuity Inc. | Methods of measuring signaling pathway activity for selection of therapeutic agents |
DK3612519T3 (da) | 2017-04-18 | 2022-03-07 | Lilly Co Eli | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl forbindelser |
AU2018277256A1 (en) | 2017-05-31 | 2020-01-30 | Prometheus Biosciences, Inc. | Methods for assessing mucosal healing in Crohn's disease patients |
JP7328960B2 (ja) | 2017-10-10 | 2023-08-17 | プロメテウス バイオサイエンシーズ インコーポレイテッド | ベドリズマブ処置をモニタリングするための方法 |
JP7109719B2 (ja) | 2018-02-14 | 2022-08-01 | 住友ゴム工業株式会社 | 特定細胞捕捉方法 |
JP7158671B2 (ja) | 2018-02-14 | 2022-10-24 | 住友ゴム工業株式会社 | 特定細胞捕捉方法 |
CA3095156A1 (en) | 2018-03-26 | 2019-10-03 | Icahn School Of Medicine At Mount Sinai | Methods of treating minimal residual cancer |
US10871485B2 (en) | 2018-04-13 | 2020-12-22 | Rarecyte, Inc. | Kits for labeling of biomarkers and methods of using the same |
US11614440B2 (en) | 2019-01-24 | 2023-03-28 | Sumitomo Rubber Industries, Ltd. | Specific cell fractionating and capturing methods |
JP6886667B2 (ja) * | 2019-03-27 | 2021-06-16 | 住友ゴム工業株式会社 | がん細胞捕捉方法 |
AU2021327387A1 (en) | 2020-08-21 | 2023-05-04 | Genzyme Corporation | Fgfr3 antibodies and methods of use |
CN113929764B (zh) * | 2021-10-15 | 2023-12-29 | 中山大学孙逸仙纪念医院 | 一种乳腺叶状肿瘤分子标志物cd146及其应用 |
Family Cites Families (133)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4233402A (en) | 1978-04-05 | 1980-11-11 | Syva Company | Reagents and method employing channeling |
US5516931A (en) * | 1982-02-01 | 1996-05-14 | Northeastern University | Release tag compounds producing ketone signal groups |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4690890A (en) | 1984-04-04 | 1987-09-01 | Cetus Corporation | Process for simultaneously detecting multiple antigens using dual sandwich immunometric assay |
SE8500817D0 (sv) | 1985-02-20 | 1985-02-20 | Lars Jonsson | Halvoppet anestesisystem |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
US4959306A (en) * | 1986-11-28 | 1990-09-25 | Sclavo, Inc. | Labeling design for a binding assay reagent |
US4975532A (en) | 1986-11-28 | 1990-12-04 | Sclavo, Inc. | Method to derivatize dextran |
JPH01163661A (ja) | 1987-10-02 | 1989-06-27 | E I Du Pont De Nemours & Co | IgG捕捉抗体および多重単クローン性抗体検出系を用いたイムノアツセイ |
US4855241A (en) * | 1988-05-26 | 1989-08-08 | Washington University | Tumor diagnostic method |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
US5192660A (en) | 1989-04-24 | 1993-03-09 | The United States Of America As Represented By The Department Of Health And Human Services | ELISA methods for the determination of human platelet derived growth factor (PDGF) dimer forms present in human tissues and fluids |
US5089419A (en) | 1989-08-07 | 1992-02-18 | International Canine Genetics | Detection of pregnancy by identification of the c peptide of relaxin in the urine of animals |
US5120660A (en) | 1989-12-05 | 1992-06-09 | International Canine Genetics, Inc. | Method for canine fertility detection |
US5532138A (en) | 1990-04-26 | 1996-07-02 | Behringwerke Ag | Method and kits for determining peroxidatively active catalysts |
US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
FR2672128B1 (fr) | 1991-01-28 | 1995-08-18 | Cis Bio Int | Procede de mesure de la luminescence emise dans un dosage par luminescence. |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
US6251581B1 (en) | 1991-05-22 | 2001-06-26 | Dade Behring Marburg Gmbh | Assay method utilizing induced luminescence |
ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
EP0625200B1 (en) | 1992-02-06 | 2005-05-11 | Chiron Corporation | Biosynthetic binding protein for cancer marker |
ATE244763T1 (de) | 1992-02-11 | 2003-07-15 | Cell Genesys Inc | Erzielen von homozygotem durch zielgerichtete genetische ereignisse |
US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
US5332662A (en) | 1992-07-31 | 1994-07-26 | Syntex (U.S.A.) Inc. | Methods for determining peroxidatively active substances |
EP0656064B1 (en) | 1992-08-17 | 1997-03-05 | Genentech, Inc. | Bispecific immunoadhesins |
JPH06109734A (ja) | 1992-09-30 | 1994-04-22 | S R L:Kk | 抗原の測定方法 |
US6201109B1 (en) | 1993-01-13 | 2001-03-13 | Dade Behring Marburg Gmbh | Assay for bone alkaline phosphatase |
CA2170873A1 (en) | 1993-09-03 | 1995-03-09 | Dariush Davalian | Fluorescent oxygen channeling immunoassays |
JP3825815B2 (ja) | 1994-01-31 | 2006-09-27 | 信義 清水 | 上皮細胞増殖因子レセプターに対するモノクローナル抗体の結合体ならびにその複合体およびその細胞への嵌入方法 |
US5807522A (en) | 1994-06-17 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for fabricating microarrays of biological samples |
FI98961C (fi) | 1994-08-26 | 1997-09-10 | Medix Biochemica Ab Oy | Menetelmät ja määritysvälineet parodontaalisairauden aktiivisuuden ja/tai peri-implantiitin ja/tai niiden kohonneen riskin diagnosoimiseksi |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
US5876944A (en) | 1996-06-10 | 1999-03-02 | Bayer Corporation | Method for amplification of the response signal in a sandwich immunoassay |
US6416967B2 (en) | 1996-07-12 | 2002-07-09 | Precision Therapeutics, Inc. | Method of using multicellular particulates to analyze malignant or hyperproliferative tissue |
US5728541A (en) | 1996-07-12 | 1998-03-17 | Precision Therapeutics, Inc. | Method for preparing cell cultures from biologial specimens for chemotherapeutic and other assays |
US20040023375A1 (en) | 2002-07-30 | 2004-02-05 | Precision Therapeutics, Inc. | Method for preparing cell cultures from biological specimens for chemotherapeutic and other assays |
US6057098A (en) | 1997-04-04 | 2000-05-02 | Biosite Diagnostics, Inc. | Polyvalent display libraries |
US6780582B1 (en) | 1998-07-14 | 2004-08-24 | Zyomyx, Inc. | Arrays of protein-capture agents and methods of use thereof |
US6897073B2 (en) | 1998-07-14 | 2005-05-24 | Zyomyx, Inc. | Non-specific binding resistant protein arrays and methods for making the same |
US6197599B1 (en) | 1998-07-30 | 2001-03-06 | Guorong Chin | Method to detect proteins |
US6541214B1 (en) * | 1998-11-13 | 2003-04-01 | Oregon Heath Science University | N-terminally truncated HER-2/neu protein as a cancer prognostic indicator |
RU2165081C2 (ru) | 1999-01-05 | 2001-04-10 | Ставропольский научно-исследовательский противочумный институт | Способ индикации микроорганизмов |
US6335173B1 (en) | 1999-01-12 | 2002-01-01 | Verve, Ltd. C/O James Bell | Methods for detecting an analyte of interest using tyramide coating technology |
GB9901072D0 (en) | 1999-01-19 | 1999-03-10 | Imp Cancer Res Tech | Methods for detecting changes to a macromolecular component of a cell |
US6972198B2 (en) | 1999-02-26 | 2005-12-06 | Cyclacel, Ltd. | Methods and compositions using protein binding partners |
RU2149404C1 (ru) | 1999-03-24 | 2000-05-20 | Московский НИИ глазных болезней им. Гельмгольца | Способ прогнозирования клинического течения увеальной меланомы |
US6627400B1 (en) | 1999-04-30 | 2003-09-30 | Aclara Biosciences, Inc. | Multiplexed measurement of membrane protein populations |
US6322980B1 (en) | 1999-04-30 | 2001-11-27 | Aclara Biosciences, Inc. | Single nucleotide detection using degradation of a fluorescent sequence |
US6649351B2 (en) | 1999-04-30 | 2003-11-18 | Aclara Biosciences, Inc. | Methods for detecting a plurality of analytes by mass spectrometry |
DE19926010C2 (de) | 1999-06-08 | 2003-01-30 | Bundesdruckerei Gmbh | Wert- und Sicherheitsdokument mit Sicherheitsmerkmal mit Piezo-Effekt-basierten Eigenschaften und dazugehöriges Nachweisverfahren |
US7179638B2 (en) | 1999-07-30 | 2007-02-20 | Large Scale Biology Corporation | Microarrays and their manufacture by slicing |
US7033781B1 (en) * | 1999-09-29 | 2006-04-25 | Diversa Corporation | Whole cell engineering by mutagenizing a substantial portion of a starting genome, combining mutations, and optionally repeating |
EP1224463A2 (en) * | 1999-10-08 | 2002-07-24 | Superarray, Inc. | Compositions and methods for detecting protein modification and enzymatic activity |
CA2385614A1 (en) | 1999-10-13 | 2001-04-19 | Timothy Johann | Multiplex cytokine analysis |
US7537938B2 (en) | 2000-04-28 | 2009-05-26 | Monogram Biosciences, Inc. | Biomarker detection in circulating cells |
US6511809B2 (en) | 2000-06-13 | 2003-01-28 | E. I. Du Pont De Nemours And Company | Method for the detection of an analyte by means of a nucleic acid reporter |
AU2001277245A1 (en) | 2000-08-03 | 2002-02-18 | Massachusetts Institute Of Technology | Microarrays of functional biomolecules, and uses therefor |
ATE475887T1 (de) * | 2000-09-09 | 2010-08-15 | Univ New York State Res Found | Verfahren und zusammensetzungen zur isolierung von metastatischen krebszellen und anwendung zur messung des metastatischen potentials eines krebses |
US6797481B1 (en) | 2000-10-17 | 2004-09-28 | Dade Behring Marburg Gmbh | Simultaneous screening of multiple analytes |
US7635571B2 (en) | 2000-12-07 | 2009-12-22 | Siemens Healthcare Diagnostics Products Gmbh | Amplified signal in binding assays |
DE10064827A1 (de) | 2000-12-22 | 2002-06-27 | Dade Behring Marburg Gmbh | Nachweisverfahren |
US20070111944A1 (en) * | 2001-02-16 | 2007-05-17 | Scrofani Sergio D B | Purification of vascular endothelial growth factor-B |
US20020168641A1 (en) | 2001-03-09 | 2002-11-14 | Bruce Mortensen | Fluorescein-cyanine 5 as a fluorescence resonance energy transfer pair |
US20020142361A1 (en) | 2001-03-27 | 2002-10-03 | Emmert-Buck Michael R. | Biodetection method |
WO2002084252A2 (en) | 2001-04-17 | 2002-10-24 | Xenoport, Inc. | Epitope-captured antibody display |
WO2002090964A1 (en) | 2001-05-03 | 2002-11-14 | Genometrix Genomics, Inc. | Method and apparatus to determine the performance of protein arrays |
WO2002103321A2 (en) | 2001-06-14 | 2002-12-27 | Anadys Pharmaceuticals, Inc. | Methods of screening for ligands of target molecules |
US7381535B2 (en) | 2002-07-10 | 2008-06-03 | The Board Of Trustees Of The Leland Stanford Junior | Methods and compositions for detecting receptor-ligand interactions in single cells |
US7695926B2 (en) | 2001-07-10 | 2010-04-13 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for detecting receptor-ligand interactions in single cells |
US20060269548A1 (en) | 2001-07-12 | 2006-11-30 | Kari Alitalo | Lymphatic endothelial cells materials and methods |
JP2003028874A (ja) * | 2001-07-12 | 2003-01-29 | Mitsubishi Chemicals Corp | 2段階酵素反応を用いた測定対象物質の測定法 |
US8323903B2 (en) | 2001-10-12 | 2012-12-04 | Life Technologies Corporation | Antibody complexes and methods for immunolabeling |
US20050069962A1 (en) | 2001-10-12 | 2005-03-31 | Archer Robert M | Antibody complexes and methods for immunolabeling |
US20030087311A1 (en) | 2001-11-07 | 2003-05-08 | Wolf David E. | Method of identifying energy transfer sensors for analytes |
AU2003222253A1 (en) | 2002-03-05 | 2003-09-22 | Monogram Biosciences, Inc. | Multiplex analysis using membrane-bound sensitizers |
US20030190689A1 (en) * | 2002-04-05 | 2003-10-09 | Cell Signaling Technology,Inc. | Molecular profiling of disease and therapeutic response using phospho-specific antibodies |
WO2003087761A2 (en) * | 2002-04-05 | 2003-10-23 | Cell Signaling Technology, Inc. | Molecular profiling of disease and therapeutic response using phospho-specific antibodies |
US20040229380A1 (en) | 2002-05-21 | 2004-11-18 | Po-Ying Chan-Hui | ErbB heterodimers as biomarkers |
ES2376165T3 (es) | 2002-07-15 | 2012-03-09 | F. Hoffmann-La Roche Ag | Tratamiento del c�?ncer con el anticuerpo dirigido contra erbb2 rhumab 2c4. |
FR2843126B1 (fr) | 2002-08-01 | 2006-01-27 | Cis Bio Int | "methode de determination d'une activite enzymatique endoglycosidase" |
US20040235002A1 (en) | 2002-09-20 | 2004-11-25 | Sangamo Biosciences, Inc. | Multiplex screening assays |
US20030153013A1 (en) | 2002-11-07 | 2003-08-14 | Ruo-Pan Huang | Antibody-based protein array system |
WO2004053497A2 (en) * | 2002-12-11 | 2004-06-24 | Ventana Medical Systems, Inc. | Method for predicting the response to her2-directed therapy |
WO2004071572A2 (en) | 2003-02-06 | 2004-08-26 | Genomic Health, Inc. | Gene expression markers for response to egfr inhibitor drugs |
EP1613961A4 (en) | 2003-04-01 | 2007-03-07 | Monogram Biosciences Inc | SURFACE RECEPTOR COMPLEXES AS BIOMARKERS |
US20040265938A1 (en) | 2003-06-25 | 2004-12-30 | Jose Remacle | Method for the determination of cell activation |
US7279286B2 (en) | 2003-09-11 | 2007-10-09 | Sanofi-Aventis Deutschland Gmbh | High-throughput-assay with high sensitivity for measuring of the activity of β-adrenergic receptor kinase and for determining the impact of test substances on such activity |
FI20031370A0 (fi) | 2003-09-23 | 2003-09-23 | Wallac Oy | Automaattinen hemoglobiinin määritysmenetelmä vastasyntyneiden seulontaan |
EP1681983A4 (en) | 2003-10-14 | 2008-12-10 | Monogram Biosciences Inc | RECEPTOR TYROSINE KINASE SIGNAL PATH ANALYSIS FOR DIAGNOSIS AND THERAPY |
DE602004026341D1 (de) | 2003-11-04 | 2010-05-12 | Bayer Pharmaceuticals Corp | IMMUNOHISTOCHEMISCHE VERFAHREN ZUR ÜBERWACHUNG VON pERK SPIEGELN |
CA2548394A1 (en) * | 2003-12-12 | 2005-06-30 | Bayer Pharmaceuticals Corporation | Methods for prediction and prognosis of cancer, and monitoring cancer therapy |
CA2559803A1 (en) | 2004-03-03 | 2005-10-13 | Bayer Technology Services Gmbh | Analytical platform and method for generating protein expression profiles of cell populations |
EP1751309B1 (en) | 2004-05-27 | 2015-07-22 | The Regents of The University of Colorado | Methods for prediction of clinical outcome to epidermal growth factor receptor inhibitors by cancer patients |
GT200500155A (es) | 2004-06-16 | 2006-05-15 | Terapia del càncer resistente al platino | |
US20060263837A1 (en) | 2004-06-17 | 2006-11-23 | Liu George D | Immunoassay system and method for detection of antigens |
WO2006026020A2 (en) | 2004-07-30 | 2006-03-09 | Adeza Biomedical Corporation | Oncofetal fibronectin as a marker for disease and other conditions and methods for detection of oncofetal fibronectin |
WO2006031815A2 (en) | 2004-09-13 | 2006-03-23 | Monogram Biosciences, Inc. | Methods and compositions for proximity assays |
US20080254497A1 (en) * | 2004-10-15 | 2008-10-16 | Monogram Biosciences, Inc. | Response Predictors for Erbb Pathway-Specific Drugs |
WO2006045991A1 (en) | 2004-10-25 | 2006-05-04 | Astrazeneca Ab | Method to predict whether a tumor will react to a chemotherapeutic treatment |
WO2006054991A1 (en) | 2004-11-17 | 2006-05-26 | Immunivest Corporation | Magnetic enrichment of circulating cells, fragments and debris for enabling hts proteomics and genomics in disease detection |
WO2006055739A2 (en) | 2004-11-17 | 2006-05-26 | Robert Sack | Stationary phase antibody arrays for trace protein analysis |
DE102004056794B4 (de) | 2004-11-24 | 2010-08-26 | Protagen Ag | Verwendung einer Anordnung und Verfahren zur Validierung von Bindern |
WO2006105642A1 (en) | 2005-04-05 | 2006-10-12 | British Columbia Cancer Agency | Biomarkers for the detection of lung cancer and uses thereof |
JP4851730B2 (ja) * | 2005-05-09 | 2012-01-11 | 小澤 滿 | 除塵加湿装置 |
AR053272A1 (es) | 2005-05-11 | 2007-04-25 | Hoffmann La Roche | Determinacion de responsivos a la quimioterapia |
US7771955B2 (en) | 2005-06-09 | 2010-08-10 | University Of Maryland | Affinity membrane for capture of a target biomolecule and formation thereof by site-directed immobilization of a capture biomolecule |
JP2007089548A (ja) * | 2005-09-30 | 2007-04-12 | Univ Of Tokushima | シグナル増幅方法 |
CN101008644A (zh) * | 2006-01-27 | 2007-08-01 | 陈云 | 功能性中枢神经损伤诊断检测用蛋白芯片及其制造方法 |
JP5048757B2 (ja) * | 2006-05-05 | 2012-10-17 | イェール・ユニバーシティー | 診断指標または予測指標としての細胞内局在プロフィールの使用 |
US20080108091A1 (en) * | 2006-08-07 | 2008-05-08 | Hennessy Bryan T | Proteomic Patterns of Cancer Prognostic and Predictive Signatures |
CN104198705B (zh) | 2006-09-21 | 2017-06-09 | 雀巢产品技术援助有限公司 | 检测稀有循环细胞内多种信号转导分子的基于抗体的阵列 |
BRPI0717416A2 (pt) | 2006-09-21 | 2013-11-12 | Prometheus Lab Inc | Método para realizar um imunoensaio complexo de alta produtividade, e, arranjo |
AU2007333468A1 (en) * | 2006-10-23 | 2008-06-19 | The Uab Research Foundation | Biomarkers for cancer sensitivity to an anti-cancer agent and uses thereof |
AU2007317204A1 (en) | 2006-11-10 | 2008-05-15 | Dimerix Bioscience Pty Ltd | Thyrotropin releasing hormone receptor-orexin receptor hetero-dimers/-oligomers |
EP2518508A1 (en) | 2006-11-28 | 2012-10-31 | U3 Pharma GmbH | Activated HER3 as a marker for predicting therapeutic efficacy |
WO2008117278A2 (en) | 2007-03-27 | 2008-10-02 | Rosetta Genomics Ltd. | Gene expression signature for classification of cancers |
JP2008292424A (ja) | 2007-05-28 | 2008-12-04 | Nippon Medical School | 腫瘍の検出方法 |
BRPI0813583A2 (pt) | 2007-07-13 | 2014-12-30 | Prometheus Lab Inc | Métodos para selecionar um medicamento anticâncer, para identificar a resposta de um tumor pulmonar, e para prognosticar a resposta de um paciente, e, arranjo |
EP2065475A1 (en) | 2007-11-30 | 2009-06-03 | Siemens Healthcare Diagnostics GmbH | Method for therapy prediction in tumors having irregularities in the expression of at least one VEGF ligand and/or at least one ErbB-receptor |
WO2009108637A1 (en) | 2008-02-25 | 2009-09-03 | Prometheus Laboratories, Inc. | Drug selection for breast cancer therapy using antibody-based arrays |
ES2627909T3 (es) | 2009-07-15 | 2017-08-01 | Diatech Holdings, Inc. | Selección de fármacos para el tratamiento del cáncer gástrico usando matrices basadas en anticuercuerpos |
US20120270745A1 (en) | 2009-07-15 | 2012-10-25 | Prometheus Laboratories Inc. | Drug selection for cancer therapy by profiling signal transduction proteins in ascites or pleural efflux samples |
WO2012047294A2 (en) | 2010-10-06 | 2012-04-12 | Ludwig Institute For Cancer Research Ltd | Antibodies directed against hla-b27 homodimers and methods and uses thereof in diagnosis and therapy |
US9719995B2 (en) | 2011-02-03 | 2017-08-01 | Pierian Holdings, Inc. | Drug selection for colorectal cancer therapy using receptor tyrosine kinase profiling |
US20120231965A1 (en) | 2011-02-03 | 2012-09-13 | Prometheus Laboratories Inc. | Drug selection for colorectal cancer therapy using antibody-based arrays |
US20130216523A1 (en) | 2011-03-31 | 2013-08-22 | Laboratory Corporation Of America Holdings | Methods for Facilitating Diagnosis, Prognosis and Treatment of Cancer by Detecting HER1 Expression |
KR101851425B1 (ko) | 2011-09-02 | 2018-04-23 | 네스텍 소시에테아노님 | 치료 효능 결정을 위한 신호 경로 단백질의 프로파일링 |
-
2009
- 2009-02-24 WO PCT/US2009/035013 patent/WO2009108637A1/en active Application Filing
- 2009-02-24 NZ NZ587420A patent/NZ587420A/en not_active IP Right Cessation
- 2009-02-24 NZ NZ600339A patent/NZ600339A/en not_active IP Right Cessation
- 2009-02-24 DK DK09715619.4T patent/DK2250498T3/da active
- 2009-02-24 CA CA2716826A patent/CA2716826C/en active Active
- 2009-02-24 ES ES12183659.7T patent/ES2553390T3/es active Active
- 2009-02-24 EP EP09715619A patent/EP2250498B1/en active Active
- 2009-02-24 MX MX2010009140A patent/MX2010009140A/es active IP Right Grant
- 2009-02-24 CA CA2923248A patent/CA2923248A1/en not_active Abandoned
- 2009-02-24 DK DK12183659.7T patent/DK2602623T3/da active
- 2009-02-24 EP EP12183659.7A patent/EP2602623B1/en active Active
- 2009-02-24 EP EP13164311.6A patent/EP2618146B1/en not_active Not-in-force
- 2009-02-24 ES ES09715619T patent/ES2398618T3/es active Active
- 2009-02-24 AU AU2009219437A patent/AU2009219437B2/en not_active Ceased
- 2009-02-24 CN CN200980114742.4A patent/CN102016581B/zh not_active Expired - Fee Related
- 2009-02-24 CN CN201310300562.3A patent/CN103399144B/zh not_active Expired - Fee Related
- 2009-02-24 JP JP2010547852A patent/JP5414701B2/ja not_active Expired - Fee Related
- 2009-02-24 NZ NZ617520A patent/NZ617520A/en not_active IP Right Cessation
- 2009-02-24 ES ES13164311.6T patent/ES2545760T3/es active Active
- 2009-07-28 US US12/511,017 patent/US8163499B2/en not_active Expired - Fee Related
-
2010
- 2010-08-16 IL IL207637A patent/IL207637A/en not_active IP Right Cessation
-
2012
- 2012-04-04 US US13/439,737 patent/US8609349B2/en not_active Expired - Fee Related
- 2012-11-05 IL IL222872A patent/IL222872A/en active IP Right Grant
-
2013
- 2013-03-14 IL IL225241A patent/IL225241A/en not_active IP Right Cessation
- 2013-05-14 JP JP2013102165A patent/JP5852047B2/ja not_active Expired - Fee Related
- 2013-08-19 HK HK13109645.5A patent/HK1182441A1/zh not_active IP Right Cessation
- 2013-11-15 HK HK13112827.9A patent/HK1185414A1/xx not_active IP Right Cessation
- 2013-11-26 US US14/091,114 patent/US9274116B2/en not_active Expired - Fee Related
-
2016
- 2016-01-12 US US14/993,813 patent/US10436786B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2250498T3 (da) | Lægemiddelvalg til brystcancerterapi under anvendelse af antistof-baserede arrays | |
EP2454598A4 (en) | ACTIVE SUBSTANCE SELECTION FOR ANTIBODY ARRAYS | |
IL227009B (en) | Drug selection for malignant cancer therapy using antibody-based arrays | |
DK3401334T3 (da) | Monoklonale antistoffer mod claudin-18 til cancerbehandling | |
DK2121139T3 (da) | Formulations for cancer treatment | |
ZA201000310B (en) | Drug selection for lung cancer therapy using antibody-based arrays | |
BRPI1006438A2 (pt) | terapia adjuvante de cancer | |
DK2346552T4 (da) | Lægemiddelafgivelsesanordning og fremgangsmåde til fremstilling af en lægemiddelafgivelsesanordning | |
DK3289876T3 (da) | Forbindelser til behandling af cancer | |
DK2076289T3 (da) | Fremgangsmåder til behandling af cancerresistens over for ErbB-lægemider | |
DK3192529T3 (da) | Amatoksin-holdige terapeutiske celleoverflade-bindingskomponenter designet til tumorterapi | |
BRPI0810206A2 (pt) | Método de tratar câncer | |
DK2195015T3 (da) | Sammensætning til behandling af prostatacancer | |
BR112012005594A2 (pt) | tratamento de câncer | |
DE602009000539D1 (de) | Strahlentherapiegerät | |
ATE478053T1 (de) | Neuartige verbindungen | |
DE602008000456D1 (de) | Strahlentherapievorrichtung | |
BRPI0918178A2 (pt) | anticorpos monoclonais para tratamento de câncer | |
DK2162149T3 (da) | Vaccine til forebyggelse af brystkræfttilbagefald | |
DK2440230T3 (da) | Behandlingsregimener til behandling af neurologisk sygdom | |
DK3106875T3 (da) | Fremgangsmåde til detektering af cancer | |
BR112012002797A2 (pt) | tratamento de câncer de próstata | |
BRPI0918064A2 (pt) | distribuidor de substância | |
DK3276004T3 (da) | Fremgangsmåder til behandling af kronisk nyresygdom | |
BRPI0820410A2 (pt) | Lactans substituídos terapêuticos |